4/17
04:15 pm
nbtx
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Low
Report
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
4/10
04:15 pm
nbtx
Voting Rights and Shares Capital of the Company
Medium
Report
Voting Rights and Shares Capital of the Company
4/2
04:15 pm
nbtx
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Low
Report
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
2/13
04:15 pm
nbtx
Voting Rights and Shares Capital of the Company
Low
Report
Voting Rights and Shares Capital of the Company
1/31
04:34 pm
nbtx
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference [Yahoo! Finance]
Low
Report
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference [Yahoo! Finance]
1/31
04:15 pm
nbtx
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
Low
Report
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
1/30
11:18 am
nbtx
Baillie Gifford Bolsters Stake in Nanobiotix SA [Yahoo! Finance]
Medium
Report
Baillie Gifford Bolsters Stake in Nanobiotix SA [Yahoo! Finance]
1/29
04:30 pm
nbtx
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study [Yahoo! Finance]
Low
Report
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study [Yahoo! Finance]
1/29
04:15 pm
nbtx
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
Low
Report
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study